Delve Bio Presents Data Showing Metagenomic Next-Generation Sequencing (mNGS) Delivers Greater Diagnostic Yield Than Conventional Methods in Central Nervous System Infections

BOSTON -- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data from a seven-year study showing mNGS delivered the highest diagnostic yield of any test, identifying more pathogens than all other methods of direct organism detection (culture, antigen testing, PCR) combined. The findings were presented at the Association for Molecular Pathology 2024 Annual Meeting in Vancouver, B.C. Read More